Taxotere Would Be Unaffected By Alimta Approval, Aventis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis expects Taxotere growth to remain unchanged should FDA approve Lilly's thymidylate synthase inhibitor Alimta for the treatment of second line non-small cell lung cancer